Onco PanScan™️ (tissue/blood)
Combined with Genetron’s universal tumor database, the solid tumor 825 genes testing covers an updated version of the WHO, NCCN, ESMO and other authoritative guidelines and expert consensus recommended test genes. Based on the high-throughput, highly sensitive NGS platform and 'hybrid capture' technology, solid tumor 825 genes testing can provide multi-dimensional immunotherapy related biomarker detection (TMB, MSI, PD-L1, immune efficacy related gene variation), so as to guide the individualized diagnosis and treatment of tumor patients more accurately, It also provides more comprehensive reference information for researchers.
1. Focus on 238 tumor drugs, covering 12 classic tumor signaling pathways, 45 chemotherapy drug related sites, 90 immunotherapy related genes, 149 tumor genetic susceptibility genes
2. Comprehensive and real-time dynamic monitoring of recurrent metastasis and the mechanism of molecular change in drug-resistant patients, to achieve the full course of cancer monitoring and management
3. Multi-dimensional immunotherapy assessment
Suitable Patient Profile:
Tumor patients seeking more opportunities for targeted drugs or immunotherapy